Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
Authors Gong S, Hu H, Zhao K, Yang T
Received 23 August 2020
Accepted for publication 11 December 2020
Published 23 February 2021 Volume 2021:16 Pages 433—441
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Shiyi Gong,1 Hao Hu,2 Kun Zhao,2 Ting Yang1
1Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Disease; Institute of Respiratory Medicine, Chinese Academy of Medical Science; Peking University Health Science Center, Beijing, People’s Republic of China; 2China National Health Development Research Center, National Health Commission of the People’s Republic of China, Beijing, People’s Republic of China
Correspondence: Ting YangDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Disease; Peking University Health Science Center; Institute of Respiratory Medicine, Chinese Academy of Medical Science
Peking University Health Science Center, No. 2 Yinghua East Street, Chaoyang District, Beijing, People’s Republic of China
Tel +86 13651380809
Background: Indacaterol/glycopyrronium (IND/GLY) is a once-daily dual bronchodilator for long-term treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy and safety of IND/GLY have been proved before, but the cost-effectiveness is unknown in China.
Purpose: This study assessed cost-effectiveness of IND/GLY comparing with salmeterol/fluticasone (SAL/FLU) and tiotropium.
Methods: A patient-level simulation model was established from Chinese payer perspective. Patient parameters were randomly simulated through resampling from parameter distributions based on clinical trials and China-specific cost data to represent individual level health state and health state transitions in the model. We simulated patient-level health state, costs, life years (LYs) and quality-adjusted life years (QALYs) of whole life horizon to evaluate the cost-effectiveness of IND/GLY comparing with SAL/FLU and tiotropium respectively.
Results: Comparing with SAL/FLU, IND/GLY resulted in 0.384 LYs and 0.255 QALYs gained. The incremental cost-effectiveness ratio (ICER) is − 35,822 CNY/LY and the incremental cost-utility ratio (ICUR) is − 53,834 CNY/QALY for IND/GLY versus SAL/FLU. Comparing with tiotropium, IND/GLY resulted in 0.232 LYs and 0.146 QALYs gained. The ICER is 39,729 CNY/LY and the ICUR is 63,246 CNY/QALY for IND/GLY versus tiotropium.
Conclusion: This study found that dual bronchodilator IND/GLY is cost-effective for stable COPD treatment in China from Chinese payer’s perspective.
Keywords: chronic obstructive pulmonary disease; COPD, dual bronchodilator, cost-effectiveness analysis, China
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]